

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the treatment and prevention... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-974/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-974" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges.">
            <meta name="og:description" content="Read the latest article version by Dominique Farge, Corinne Frere, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20447">
            <meta name="article-id" content="18673">
            <meta name="dc.title" content="Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges">
            <meta name="dc.description" content="Venous thromboembolism (VTE) is a common complication in patients with cancer and is associated with poor prognosis. Low-molecular-weight heparins (LMWHs) are the standard of care for the treatment of cancer-associated thrombosis. Primary VTE prophylaxis with LMWH is recommended after cancer surgery and in hospitalized patients with reduced mobility. However, owing to wide variations in VTE and bleeding risk, based on disease stage, anti-cancer treatments, and individual patient characteristics, routine primary prophylaxis is not recommended in ambulatory cancer patients undergoing chemotherapy. Efforts are under way to validate risk assessment models that will help identify those patients in whom the benefits of primary prophylaxis will outweigh the risks. In recent months, long-awaited dedicated clinical trials assessing the direct oral anticoagulants (DOACs) in patients with cancer have reported promising results. In comparison with the LMWHs, the DOACs were reported to be non-inferior to prevent VTE recurrence. However, there was an increased risk of bleeding, particularly in gastrointestinal cancers. Safe and optimal treatment with the DOACs in the patient with cancer will require vigilant patient selection based on patient characteristics, co-morbidities, and the potential for drug&ndash;drug interactions.">
            <meta name="dc.subject" content="venous thromboembolism, cancer, low molecular weight heparin, direct oral anticoagulant">
            <meta name="dc.creator" content="Farge, Dominique">
            <meta name="dc.creator" content="Frere, Corinne">
            <meta name="dc.date" content="2019/06/27">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18673.1">
            <meta name="dc.source" content="F1000Research 2019 8:974">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="venous thromboembolism">
            <meta name="prism.keyword" content="cancer">
            <meta name="prism.keyword" content="low molecular weight heparin">
            <meta name="prism.keyword" content="direct oral anticoagulant">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/06/27">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="974">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18673.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-974">
            <meta name="citation_title" content="Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges">
            <meta name="citation_abstract" content="Venous thromboembolism (VTE) is a common complication in patients with cancer and is associated with poor prognosis. Low-molecular-weight heparins (LMWHs) are the standard of care for the treatment of cancer-associated thrombosis. Primary VTE prophylaxis with LMWH is recommended after cancer surgery and in hospitalized patients with reduced mobility. However, owing to wide variations in VTE and bleeding risk, based on disease stage, anti-cancer treatments, and individual patient characteristics, routine primary prophylaxis is not recommended in ambulatory cancer patients undergoing chemotherapy. Efforts are under way to validate risk assessment models that will help identify those patients in whom the benefits of primary prophylaxis will outweigh the risks. In recent months, long-awaited dedicated clinical trials assessing the direct oral anticoagulants (DOACs) in patients with cancer have reported promising results. In comparison with the LMWHs, the DOACs were reported to be non-inferior to prevent VTE recurrence. However, there was an increased risk of bleeding, particularly in gastrointestinal cancers. Safe and optimal treatment with the DOACs in the patient with cancer will require vigilant patient selection based on patient characteristics, co-morbidities, and the potential for drug&ndash;drug interactions.">
            <meta name="citation_description" content="Venous thromboembolism (VTE) is a common complication in patients with cancer and is associated with poor prognosis. Low-molecular-weight heparins (LMWHs) are the standard of care for the treatment of cancer-associated thrombosis. Primary VTE prophylaxis with LMWH is recommended after cancer surgery and in hospitalized patients with reduced mobility. However, owing to wide variations in VTE and bleeding risk, based on disease stage, anti-cancer treatments, and individual patient characteristics, routine primary prophylaxis is not recommended in ambulatory cancer patients undergoing chemotherapy. Efforts are under way to validate risk assessment models that will help identify those patients in whom the benefits of primary prophylaxis will outweigh the risks. In recent months, long-awaited dedicated clinical trials assessing the direct oral anticoagulants (DOACs) in patients with cancer have reported promising results. In comparison with the LMWHs, the DOACs were reported to be non-inferior to prevent VTE recurrence. However, there was an increased risk of bleeding, particularly in gastrointestinal cancers. Safe and optimal treatment with the DOACs in the patient with cancer will require vigilant patient selection based on patient characteristics, co-morbidities, and the potential for drug&ndash;drug interactions.">
            <meta name="citation_keywords" content="venous thromboembolism, cancer, low molecular weight heparin, direct oral anticoagulant">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Dominique Farge">
            <meta name="citation_author_institution" content="Universit&eacute; de Paris, IRSL, Paris, France">
            <meta name="citation_author_institution" content="Assistance Publique H&ocirc;pitaux de Paris, Saint-Louis Hospital, Internal Medicine, Autoimmune and Vascular Disease Unit, Paris, France">
            <meta name="citation_author_institution" content="McGill University, Montral, QC, Canada">
            <meta name="citation_author" content="Corinne Frere">
            <meta name="citation_author_institution" content="Sorbonne Universit&eacute;, INSERM UMRS_1166, Institute of Cardiometabolism And Nutrition, Paris, France">
            <meta name="citation_author_institution" content="Assistance Publique H&ocirc;pitaux de Paris, Piti&eacute;-Salp&ecirc;tri&egrave;re Hospital, Department of Haematology, Paris, France">
            <meta name="citation_publication_date" content="2019/06/27">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="974">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18673.1">
            <meta name="citation_firstpage" content="974">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-974/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-974.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20447 /> <input type=hidden id=articleId name=articleId value=18673 /> <input type=hidden id=xmlUrl value="/articles/8-974/v1/xml"/> <input type=hidden id=xmlFileName value="-8-974-v1.xml"> <input type=hidden id=article_uuid value=e876fd4b-5939-4a2a-8c26-b54904e4c43d /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18673.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18673.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-974"
  },
  "headline": "Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the...",
  "datePublished": "2019-06-27T09:29:26",
  "dateModified": "2019-06-27T09:29:26",
  "author": [
    {
      "@type": "Person",
      "name": "Dominique Farge"
    },    {
      "@type": "Person",
      "name": "Corinne Frere"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Venous thromboembolism (VTE) is a common complication in patients with cancer and is associated with poor prognosis. Low-molecular-weight heparins (LMWHs) are the standard of care for the treatment of cancer-associated thrombosis. Primary VTE prophylaxis with LMWH is recommended after cancer surgery and in hospitalized patients with reduced mobility. However, owing to wide variations in VTE and bleeding risk, based on disease stage, anti-cancer treatments, and individual patient characteristics, routine primary prophylaxis is not recommended in ambulatory cancer patients undergoing chemotherapy. Efforts are under way to validate risk assessment models that will help identify those patients in whom the benefits of primary prophylaxis will outweigh the risks. In recent months, long-awaited dedicated clinical trials assessing the direct oral anticoagulants (DOACs) in patients with cancer have reported promising results. In comparison with the LMWHs, the DOACs were reported to be non-inferior to prevent VTE recurrence. However, there was an increased risk of bleeding, particularly in gastrointestinal cancers. Safe and optimal treatment with the DOACs in the patient with cancer will require vigilant patient selection based on patient characteristics, co-morbidities, and the potential for drug&ndash;drug interactions."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-974.html",
            "name": "Recent advances in the treatment and prevention of venous thromboembolism..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the treatment and prevention of venous thromboembolism... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20447 data-id=18673 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18673.1" data-recommended="" data-doi="10.12688/f1000research.18673.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-974/v1/pdf?article_uuid=e876fd4b-5939-4a2a-8c26-b54904e4c43d" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18673-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18673-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18673-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Farge D and Frere C. Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):974 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18673.1" target=_blank>https://doi.org/10.12688/f1000research.18673.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18673-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18673 id=track-article-signin-18673 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18673?target=/articles/8-974.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20447 /> <input name=articleId type=hidden value=18673 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:dominique.farge-bancel@aphp.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Dominique Farge</span></a><a href="https://orcid.org/0000-0002-4041-1352" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4041-1352</div><sup>1-3</sup>,&nbsp;</span><span class="">Corinne Frere<a href="https://orcid.org/0000-0001-6303-4732" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6303-4732</div><sup>4,5</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:dominique.farge-bancel@aphp.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Dominique Farge</span></a><a href="http://orcid.org/0000-0002-4041-1352" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4041-1352</div><sup>1-3</sup>,&nbsp;</span><span class="">Corinne Frere<a href="http://orcid.org/0000-0001-6303-4732" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6303-4732</div><sup>4,5</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 27 Jun 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18673.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Universit&eacute; de Paris, IRSL, Paris, France<br/> <sup>2</sup> Assistance Publique H&ocirc;pitaux de Paris, Saint-Louis Hospital, Internal Medicine, Autoimmune and Vascular Disease Unit, Paris, France<br/> <sup>3</sup> McGill University, Montral, QC, Canada<br/> <sup>4</sup> Sorbonne Universit&eacute;, INSERM UMRS_1166, Institute of Cardiometabolism And Nutrition, Paris, France<br/> <sup>5</sup> Assistance Publique H&ocirc;pitaux de Paris, Piti&eacute;-Salp&ecirc;tri&egrave;re Hospital, Department of Haematology, Paris, France<br/> <p> <div class=margin-bottom> Dominique Farge <br/> <span>Roles: </span> Investigation, Methodology, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Corinne Frere <br/> <span>Roles: </span> Investigation, Methodology, Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53010-50501></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53011-50502></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Venous thromboembolism (VTE) is a common complication in patients with cancer and is associated with poor prognosis. Low-molecular-weight heparins (LMWHs) are the standard of care for the treatment of cancer-associated thrombosis. Primary VTE prophylaxis with LMWH is recommended after cancer surgery and in hospitalized patients with reduced mobility. However, owing to wide variations in VTE and bleeding risk, based on disease stage, anti-cancer treatments, and individual patient characteristics, routine primary prophylaxis is not recommended in ambulatory cancer patients undergoing chemotherapy. Efforts are under way to validate risk assessment models that will help identify those patients in whom the benefits of primary prophylaxis will outweigh the risks. In recent months, long-awaited dedicated clinical trials assessing the direct oral anticoagulants (DOACs) in patients with cancer have reported promising results. In comparison with the LMWHs, the DOACs were reported to be non-inferior to prevent VTE recurrence. However, there was an increased risk of bleeding, particularly in gastrointestinal cancers. Safe and optimal treatment with the DOACs in the patient with cancer will require vigilant patient selection based on patient characteristics, co-morbidities, and the potential for drug–drug interactions. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> venous thromboembolism, cancer, low molecular weight heparin, direct oral anticoagulant </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Dominique Farge (<a href="mailto:dominique.farge-bancel@aphp.fr">dominique.farge-bancel@aphp.fr</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Dominique Farge </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Farge D and Frere C. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Farge D and Frere C. Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):974 (<a href="https://doi.org/10.12688/f1000research.18673.1" target=_blank>https://doi.org/10.12688/f1000research.18673.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 27 Jun 2019, <b>8</b>(F1000 Faculty Rev):974 (<a href="https://doi.org/10.12688/f1000research.18673.1" target=_blank>https://doi.org/10.12688/f1000research.18673.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 27 Jun 2019, <b>8</b>(F1000 Faculty Rev):974 (<a href="https://doi.org/10.12688/f1000research.18673.1" target=_blank>https://doi.org/10.12688/f1000research.18673.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d37824e183>Introduction</h2><p class="" id=d37824e186>Data from large registries indicate that the risk of developing venous thromboembolism (VTE) is four- to seven-fold greater for cancer patients compared with non-cancer patients, and the incidence of cancer-associated thrombosis (CAT) is increasing worldwide<sup><a href="#ref-1">1</a>–<a href="#ref-5">5</a></sup>. As many as half of CAT cases are incidentally detected<sup><a href="#ref-6">6</a></sup>. Multiple factors contribute to the risk of CAT; these include cancer type and stage, surgery, medical anti-cancer therapies, central venous catheter use, treatments for co-morbidities, and individual patient characteristics, such as extremes in body weight, malnutrition, and advanced age<sup><a href="#ref-7">7</a></sup>. Thromboembolism is the second leading cause of death after cancer progression in this patient population<sup><a href="#ref-2">2</a></sup>. CAT is a marker of poor prognosis; cancer patients who develop VTE are six times less likely to survive than cancer patients without VTE<sup><a href="#ref-1">1</a></sup>. Management of VTE with anticoagulant therapies in patients with cancer is challenging because these patients are more likely to experience VTE recurrence and major bleeding events on anticoagulants relative to non-cancer patients<sup><a href="#ref-8">8</a></sup>, which may be explained by expression of fibrinolytic factors by malignant cells, disseminated intravascular coagulation and thrombocytopenia, vascular invasion, and certain anti-cancer therapies<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>.</p><p class="" id=d37824e224>Low-molecular-weight heparins (LMWHs) have been recommended over vitamin K antagonists (VKAs) as the first-line treatment for CAT for over 15 years<sup><a href="#ref-11">11</a></sup> on the basis of three positive (CANTHANOX<sup><a href="#ref-12">12</a></sup>, CLOT<sup><a href="#ref-13">13</a></sup>, and LITE<sup><a href="#ref-14">14</a></sup>) out of five (CANTHANOX<sup><a href="#ref-12">12</a></sup>, CLOT<sup><a href="#ref-13">13</a></sup>, LITE<sup><a href="#ref-14">14</a></sup>, ONCENOX<sup><a href="#ref-15">15</a></sup>, and CATCH<sup><a href="#ref-16">16</a></sup>) randomized controlled trials (RCTs) which demonstrated that LMWHs are more effective and at least as safe as VKAs. LMWHs are recommended for at least 3 to 6 months for the treatment of established VTE<sup><a href="#ref-17">17</a>–<a href="#ref-22">22</a></sup>. Primary VTE prophylaxis is recommended for cancer surgery and hospitalized patients with reduced mobility but is not recommended routinely in ambulatory cancer patients receiving systemic anti-cancer treatments.</p><p class="" id=d37824e271>Despite being the best anticoagulant option in patients with cancer, the use of a parenteral anticoagulant is sometimes a barrier to treatment and may result in low treatment compliance. In addition, the cost of LMWH treatment is prohibitive in certain health-care systems. In recent years, direct oral anticoagulants (DOACs) have become an alternative to LMWH for the treatment of CAT. Like LMWH, DOACs have a rapid onset of action with predictable pharmacodynamics, but they have the convenience of oral administration. Initial evidence supporting the use of DOACs in the treatment of CAT was provided by analyses of cancer patient subgroups (3–9%)<sup><a href="#ref-23">23</a>–<a href="#ref-29">29</a></sup> included in the landmark DOAC trials, which were conducted in the general patient population<sup><a href="#ref-30">30</a>–<a href="#ref-35">35</a></sup>. In the past two years, dedicated head-to-head trials in the cancer patient population have been published with promising results<sup><a href="#ref-36">36</a>–<a href="#ref-40">40</a></sup>. Although DOACs offer certain advantages over parenteral anticoagulants, they present their own set of unique treatment challenges that require appropriate patient selection for their use. Here, we summarize the new evidence on DOAC anticoagulant therapy in cancer patients and still-unanswered questions and controversies in the field.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d37824e298>New evidence for the use of DOACs in patients with cancer</h2><div class=section><a name=d37824e301 class=n-a></a><h3 class=section-title>Treatment and secondary prophylaxis of established cancer-associated VTE</h3><p class="" id=d37824e306>Results from three dedicated RCTs assessing the safety and efficacy of the DOACs in the treatment of CAT patients compared with LMWH have recently become available<sup><a href="#ref-36">36</a>–<a href="#ref-38">38</a></sup>.</p><p class="" id=d37824e316>The patients included in these trials reflect a more representative cross-section of the overall cancer patient population; more than half of participants had a metastatic disease (53.0–65.5%) and more than two thirds were receiving systemic anti-cancer therapy (70.0–74.0%). All studies excluded patients with an ECOG (Eastern Cooperative Oncology Group) score of more than 2. The rates of VTE recurrence and major bleeding in the LMWH groups across DOAC studies are consistent with the rates documented in the landmark trials which demonstrated the superiority of LMWH over VKA (CANTHANOX<sup><a href="#ref-12">12</a></sup>, CLOT<sup><a href="#ref-13">13</a></sup>, and LITE<sup><a href="#ref-14">14</a></sup>) to prevent VTE recurrence in cancer patients with no increase in bleeding.</p><p class="" id=d37824e331>The Hokusai-VTE<sup><a href="#ref-36">36</a></sup> and SELECT-D<sup><a href="#ref-37">37</a></sup> trials compared the safety and efficacy of DOAC and LMWH in the treatment of established CAT (<a href="#T1">Table 1</a>). In Hokusai-VTE<sup><a href="#ref-36">36</a></sup>, 1050 cancer patients with symptomatic or incidentally diagnosed VTE were randomly assigned to either edoxaban (60 mg daily after at least 5 days of LMWH therapy) or dalteparin (200 IU/kg daily for 1 month followed by 150 IU/kg daily) for 6 to 12 months. Edoxaban was non-inferior to LMWH in the composite primary outcome measure of recurrent VTE or major bleeding within 12 months after randomization regardless of treatment duration (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.70–1.36, <i>P</i> = 0.006 for non-inferiority, <i>P</i> = 0.87 for superiority). An analysis of the components of the primary outcome measure demonstrated that VTE recurrence rates were numerically lower with edoxaban, but that this difference was not statistically significant (7.9% [edoxaban] versus 11.3% [dalteparin], <i>P</i> = 0.09). Major bleeding was more common with edoxaban (6.9% versus 4.0%, <i>P</i> = 0.04), whereas rates of clinically relevant non-major bleeding and mortality were similar between groups. The higher rate of major bleeding in the edoxaban group was driven by gastrointestinal (GI) bleeding in patients with GI cancer. In Hokusai-VTE, patients were excluded if the need for several P-glycoprotein (P-gp) inhibitors, such as ritonavir, nelfinavir, indinavir, or saquinavir, was anticipated. Systemic use of other P-gp inhibitors, namely etoconazole, itraconazole, erythromycin, azithromycin, or clarithromycin, was not permitted at inclusion but was permitted if needed during the study with appropriate dose adjustments of edoxaban.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Randomized clinical trials assessing the efficacy and safety of direct oral anticoagulants in the treatment of cancer-associated thrombosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d37824e373 class=n-a></a><thead><a name=d37824e375 class=n-a></a><tr><a name=d37824e377 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e379 class=n-a></a>Randomized clinical trials</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e382 class=n-a></a>Hokusai-VTE cancer<sup><a href="#ref-36">36</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e388 class=n-a></a>SELECT-D<sup><a href="#ref-37">37</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e394 class=n-a></a>ADAM-VTE<sup><a href="#ref-38">38</a></sup></th></tr></thead><tbody><a name=d37824e402 class=n-a></a><tr><a name=d37824e404 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e406 class=n-a></a>Number of randomly<br class=br>assigned patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e411 class=n-a></a>1050</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e414 class=n-a></a>406</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e417 class=n-a></a>300</td></tr><tr><a name=d37824e421 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e423 class=n-a></a>Trial design</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e426 class=n-a></a>Non-inferiority</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e429 class=n-a></a>Pilot</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e432 class=n-a></a>Superiority</td></tr><tr><a name=d37824e436 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e438 class=n-a></a>DOAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e441 class=n-a></a>Edoxaban: Dalteparin for at least<br class=br>5 days followed by edoxaban 60 mg<br class=br>once daily for 6 to 12 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e448 class=n-a></a>Rivaroxaban: 15 mg twice daily<br class=br>for 3 weeks followed by 20 mg<br class=br>once daily for 2 to 6 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e455 class=n-a></a>Apixaban: 10 mg twice daily for<br class=br>7 days followed by 5 mg twice<br class=br>daily for 6 months</td></tr><tr><a name=d37824e463 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e465 class=n-a></a>Comparator</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e468 class=n-a></a>LMWH: Daltaparin 200 IU/kg once<br class=br>daily first 30 days followed by<br class=br>150 IU/kg daily </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e475 class=n-a></a>LMWH: Daltaparin 200 IU/kg<br class=br>once daily first 30 days followed<br class=br>by 150 IU/kg daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e482 class=n-a></a>LMWH: Daltaparin 200 IU/kg once<br class=br>daily first 30 days followed by 150<br class=br>IU/kg daily</td></tr><tr><a name=d37824e490 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e492 class=n-a></a>Primary outcome measures</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e495 class=n-a></a>Composite measure of recurrent<br class=br>VTE or major bleeding within<br class=br>12 months after randomization </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e502 class=n-a></a>VTE recurrence in the 6 months<br class=br>after randomization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e507 class=n-a></a>Major bleeding including fatal<br class=br>bleeding </td></tr><tr><a name=d37824e514 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e516 class=n-a></a>Primary outcome results</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e519 class=n-a></a>•&nbsp;&nbsp;Edoxaban: 12.8%<br class=br>•&nbsp;&nbsp;Dalteparin: 13.5% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e524 class=n-a></a>•&nbsp;&nbsp;Rivaroxaban: 4%<br class=br>•&nbsp;&nbsp;Dalteparin: 11%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e529 class=n-a></a>•&nbsp;&nbsp;Apixaban: 0%<br class=br>•&nbsp;&nbsp;Dalteparin: 2.1%</td></tr><tr><a name=d37824e535 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e537 class=n-a></a>Major secondary outcomes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e540 class=n-a></a>Recurrent VTE<br class=br>•&nbsp;&nbsp;Edoxaban: 7.9%<br class=br>•&nbsp;&nbsp;Dalteparin: 11.3%<br class=br>Major bleeding<br class=br>•&nbsp;&nbsp;Edoxaban: 6.9%<br class=br>•&nbsp;&nbsp;Dalteparin: 4.0% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e553 class=n-a></a>Major bleeding<br class=br>•&nbsp;&nbsp;Rivaroxaban: 13%<br class=br>•&nbsp;&nbsp;Dalteparin: 4%<br class=br>CRNMB<br class=br>•&nbsp;&nbsp;Rivaroxaban: 6%<br class=br>•&nbsp;&nbsp;Dalteparin: 4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e566 class=n-a></a>Recurrent VTE (DVT, PE, fatal PE)<br class=br>•&nbsp;&nbsp;Apixaban: 3.4%<br class=br>•&nbsp;&nbsp;Dalteparin: 14.1%<br class=br>•&nbsp;&nbsp;Major + fatal + CRNMB<br class=br>•&nbsp;&nbsp;Apixaban: 9.0%<br class=br>•&nbsp;&nbsp;Dalteparin: 9.0%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d37824e584 class=n-a></a><p id=d37824e586> CRNMB, clinically relevant non-major bleeding; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism.</p></div></div></div><p class="" id=d37824e593>In the SELECT-D pilot trial<sup><a href="#ref-37">37</a></sup>, 406 cancer patients with symptomatic or incidental pulmonary embolism (PE) or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were randomly assigned to rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) or dalteparin (200 IU/kg daily for 1 month followed by 150 IU/kg daily). The 6-month cumulative rate of recurrent VTE after randomization was significantly lower with rivaroxaban compared with dalteparin (HR 0.43, 95% CI 0.19–0.99). Cumulative clinically relevant non-major bleeding rates were higher with rivaroxaban (HR 3.76, 95% CI 1.63–8.69), but major bleeding rates were not statistically different between the groups (6% [rivaroxaban] versus 4% [dalteparin], HR 1.83, 95% CI 0.68–4.96). Of note, during the interim analysis, the data and safety monitoring study committee determined that although the overall bleeding events did not cross the safety boundary of excess in clinically relevant bleeding, the patients with esophageal or esophagogastric junction tumors had a trend toward major bleeding. Therefore, as a precaution, such types of patients were subsequently excluded from enrollment. Six-month survival did not differ between the two treatment arms. Major bleeding occurred more frequently with rivaroxaban than with dalteparin in patients with esophageal or gastroesophageal cancer (36% [rivaroxaban] versus 11% [dalteparin]). Most major bleeding events in the rivaroxaban group were GI. Most clinically relevant non-major bleeding events occurring with rivaroxaban were GI or genitourinary. Concomitant use of the following strong cytochrome P450 3A4 inhibitors or inducers was excluded: human immunodeficiency virus protease inhibitors or systemic ketoconazole and rifampicin, carbamazepine, or phenytoin. Concomitant use of P-gp inhibitors or inducers was excluded.</p><p class="" id=d37824e600>Results from the ADAM trial (ClinicalTrials.gov Identifier: NCT02585713)<sup><a href="#ref-38">38</a></sup> were presented in December 2018 at the 60th American Society of Hematology annual meeting. Cancer patients with established CAT, including upper-extremity and splanchnic vein thrombosis, were randomly assigned to either apixaban<b></b>(10 mg twice daily for 7 days followed by 5 mg twice daily) or dalteparin (200 IU/kg daily for 1 month followed by 150 IU/kg daily) for 6 months. The primary outcome measure of major bleeding rate was similar between the two treatment groups (0 [apixaban] versus 3/142 (2.1%) [dalteparin], <i>P</i> = 0.9956). The secondary outcome of VTE recurrence rate was lower with apixaban compared with LMWH (HR 0.26, 95% CI 0.09–0.80, <i>P</i> = 0.0182). Strong CYP3A4 inducers were excluded from the study.</p><p class="" id=d37824e615><b><i>Treatment satisfaction.</i></b> Few studies have assessed the quality of life (QoL) of cancer patients with CAT treated by LMWH. The prospective TROPIQUE (n = 409 patients with cancer)<sup><a href="#ref-41">41</a></sup> and QUAVITEC (n = 400 patients with cancer)<sup><a href="#ref-42">42</a></sup> cohort studies reported that most patients were satisfied or very satisfied and reassured about treatment efficacy and experience with side effects under LMWH, which did not hinder QoL improvements in those who survived to 6-month follow-up. In Hokusai-VTE<sup><a href="#ref-36">36</a></sup>, treatment termination as a result of inconvenience of dosing was reported in 4% of patients on edoxaban and 14.9% of patients on dalteparin. In the ADAM trial, QoL surveys in the ADAM-VTE trial<sup><a href="#ref-38">38</a></sup> revealed a better tolerance to apixaban compared with dalteparin. Premature discontinuation of anticoagulant treatment in the study occurred in significantly fewer patients receiving apixaban compared with dalteparin (15%; <i>P</i> = 0.0012).</p><p class="" id=d37824e640>In conclusion, anticoagulant therapy with the DOACs in the treatment of established CAT resulted in similar or better rates of recurrent VTE but was associated with a higher risk of bleeding, particularly in GI and genitourinary cancers. The underlying cause of the susceptibility of the GI tract to bleeding may be due to accumulation of active drug or chemotherapy toxicity<sup><a href="#ref-43">43</a></sup>. Overall, these first trials suggest a favorable risk-benefit ratio for DOACs in the treatment and secondary prevention of established CAT. However, their safe and optimal use will require appropriate patient selection and monitoring of several parameters, particularly since the theoretical risks of drug–drug interactions have not been investigated in patients with cancer.</p></div><div class=section><a name=d37824e648 class=n-a></a><h3 class=section-title>Primary prophylaxis of cancer-associated VTE</h3><p class="" id=d37824e653>About 5 to 10% of ambulatory cancer patients initiating chemotherapy will develop CAT, and up to 74% of CAT cases occur in the outpatient setting<sup><a href="#ref-44">44</a></sup>. The widely varying risk of VTE and bleeding across cancer types, stages, cancer treatments, and individual patients has resulted in study findings in this patient population that have been difficult to interpret. Two large RCTs compared LMWH with placebo in patients with different cancer types and found a significant reduction in the relative risk of VTE but with a small difference in the respective absolute risk<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. A recent systematic review and meta-analysis reported that primary prophylaxis with LMWH compared with no treatment in all cancers reduced the rate of VTE, while significantly increasing the risk of major bleeding<sup><a href="#ref-47">47</a></sup>. However, the number needed to treat was 30, supporting previous conclusions that primary prophylaxis should not be used across patients with cancer<sup><a href="#ref-47">47</a></sup>. Studies in pancreatic cancer which is associated with considerably high VTE risks yielded better risk-benefit ratios<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>.</p><p class="" id=d37824e682>Several ongoing efforts to stratify patients according to VTE risk are under way in order to identify the appropriate patients who stand to benefit from primary prophylaxis. The Khorana score<sup><a href="#ref-50">50</a></sup>, which is based on readily available clinical and laboratory parameters, was developed for ambulatory patients initiating chemotherapy and is the most widely studied risk assessment model. The model was validated in independent studies<sup><a href="#ref-51">51</a></sup>, although recent publications questioned its reproducibility in certain patient populations<sup><a href="#ref-52">52</a>–<a href="#ref-54">54</a></sup>. Several modifications of the Khorana score have been proposed to improve its predictive strength and are currently being studied, including the extended Vienna Cancer and Thrombosis Study (CATS) score<sup><a href="#ref-51">51</a></sup> and the Protecht score<sup><a href="#ref-55">55</a></sup>, as well as a simplified clinical prediction model incorporating only tumor-site category and D-dimer<sup><a href="#ref-56">56</a></sup>. The recent DOAC trials assessing the safety and efficacy of DOACs for the primary prophylaxis VTE in ambulatory cancer patients initiating chemotherapy aimed to address this issue by stratifying patients according to VTE risk (<a href="#T2">Table 2</a>)<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. The studies used the Khorana score<sup><a href="#ref-50">50</a></sup>, which continues to be the most widely accepted VTE risk assessment model in this cancer patient population.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Randomized clinical trials assessing the efficacy and safety of direct oral anticoagulants in the prophylaxis of cancer-associated thrombosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d37824e738 class=n-a></a><thead><a name=d37824e740 class=n-a></a><tr><a name=d37824e742 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e744 class=n-a></a>Randomized clinical trials</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e747 class=n-a></a>CASSINI<sup><a href="#ref-39">39</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e753 class=n-a></a>AVERT<sup><a href="#ref-40">40</a></sup></th></tr></thead><tbody><a name=d37824e761 class=n-a></a><tr><a name=d37824e763 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e765 class=n-a></a>Number of randomly assigned<br class=br>patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e770 class=n-a></a>841</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e773 class=n-a></a>574</td></tr><tr><a name=d37824e777 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e779 class=n-a></a>Trial design</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e782 class=n-a></a>Superiority</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e785 class=n-a></a>Superiority</td></tr><tr><a name=d37824e789 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e791 class=n-a></a>DOAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e794 class=n-a></a>Rivaroxaban: 10 mg once daily </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e797 class=n-a></a>Apixaban: 2.5 mg twice daily </td></tr><tr><a name=d37824e801 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e803 class=n-a></a>Comparator</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e806 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e809 class=n-a></a>Placebo</td></tr><tr><a name=d37824e813 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e815 class=n-a></a>Primary outcome measures</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e818 class=n-a></a>•&nbsp;&nbsp;Composite measure of DVT, PE,<br class=br>and VTE-related death<br class=br>•&nbsp;&nbsp;Major bleeding</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e825 class=n-a></a>•&nbsp;&nbsp;Objectively documented VTE (proximal DVT<br class=br>and PE) over a 6-month follow-up period<br class=br>•&nbsp;&nbsp;Major bleeding</td></tr><tr><a name=d37824e834 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e836 class=n-a></a>Primary outcome results</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e839 class=n-a></a>Composite on-treatment<br class=br>•&nbsp;&nbsp;Rivaroxaban: 2.6%<br class=br>•&nbsp;&nbsp;Placebo: 6.4%<br class=br>Composite – up to 6 months<br class=br>•&nbsp;&nbsp;Rivaroxaban: 6.0%<br class=br>•&nbsp;&nbsp;Placebo: 8.8%<br class=br>Major bleeding<br class=br>•&nbsp;&nbsp;Rivaroxaban: 2.0%<br class=br>•&nbsp;&nbsp;Placebo: 1.0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e859 class=n-a></a>VTE<br class=br>•&nbsp;&nbsp;Apixaban: 4.2%<br class=br>•&nbsp;&nbsp;Placebo: 10.2%<br class=br>Major bleeding<br class=br>•&nbsp;&nbsp;Apixaban: 3.5%<br class=br>•&nbsp;&nbsp;Placebo: 1.8%</td></tr><tr><a name=d37824e873 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e875 class=n-a></a>Major secondary outcomes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e878 class=n-a></a>CRNMB<br class=br>•&nbsp;&nbsp;Rivaroxaban: 2.7%<br class=br>•&nbsp;&nbsp;Placebo: 2.0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e885 class=n-a></a>CRNMB<br class=br>•&nbsp;&nbsp;Apixaban: 7.3%<br class=br>•&nbsp;&nbsp;Placebo: 5.5%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d37824e897 class=n-a></a><p id=d37824e899> CRNMB, clinically relevant non-major bleeding; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.</p></div></div></div><p class="" id=d37824e905>The CASSINI trial<sup><a href="#ref-39">39</a></sup> assessed the safety and efficacy of rivaroxaban in ambulatory cancer patients initiating chemotherapy with intermediate to high risk of VTE (Khorana score of at least 2). Eight hundred forty-one patients were randomly assigned to either treatment with rivaroxaban (10 mg once daily) or placebo for up to 6 months. The primary outcome did not differ between the groups over the entire 6-month observation period (8.8% under placebo versus 6.0% under rivaroxaban; HR 0.66, 95% CI 0.40–1.09, <i>P</i> = 0.10). Patients who received rivaroxaban compared with those under placebo while on treatment had fewer primary outcome events, which was a composite measure of symptomatic or asymptomatic DVT or PE and VTE-related death (6.4% under placebo versus 2.6% under rivaroxaban, HR 0.40, 95% CI 0.20–0.80).<b></b>There was no difference in major bleeding between the two groups (HR 1.96, 95% CI 0.59–6.49). Patients with primary or metastatic brain tumors were excluded from the study. The majority of enrolled patients had pancreatic (32.6%), gastric and gastroesophagus (20.9%), or lung (15.9%) cancer or lymphoma (7%).</p><p class="" id=d37824e918>The AVERT trial<sup><a href="#ref-40">40</a></sup> compared primary prophylaxis with apixaban (2.5 mg twice daily) with placebo in 573 ambulatory cancer patients initiating chemotherapy for up to 6 months. The primary outcome was symptomatic and incidental VTE occurrence. Patients receiving apixaban had a lower risk of VTE occurrence compared with placebo (7.3% under placebo versus 1% under apixaban, HR 0.14, 95% CI 0.26–0.65, <i>P</i> &lt;0.001). The risk of major bleeding was increased on apixaban (HR 2.00, 95% CI 1.01–3.95, <i>P</i> = 0.046). The majority of enrolled patients had gynecologic (25.7%), pancreatic (13.5%), or lung (10%) cancer or lymphoma (25.2%).</p><p class="" id=d37824e931>When results from the two studies were combined, the absolute difference in the incidence of symptomatic VTE between the DOAC and the placebo groups was 2.5% in the primary intention-to-treat analysis, which corresponds to a number needed to treat of 40 patients<sup><a href="#ref-57">57</a></sup>. Together, these DOAC studies indicate that primary prophylaxis in cancer patients with a Khorana score of at least 2 results in significantly lower rates of VTE. However, the risk of major bleeding was increased with apixaban. In both studies, patients considered to have a high bleeding risk were excluded. There was a high rate of discontinuation, in both the treatment and placebo groups.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d37824e942>Unanswered questions and controversies</h2><p class="" id=d37824e945>There are multiple disease-related factors, including drug absorption, distribution, metabolism, and elimination, that can affect anticoagulant pharmacokinetics in patients with cancer (reviewed in <a href="#ref-58">58</a>). The risks of over- or under-coagulating with DOACs, despite their predictable pharmacodynamics, as a result of renal or hepatic impairment, potential drug–drug interactions, and patient characteristics such as weight and age require vigilance (reviewed in <a href="#ref-59">59</a>,<a href="#ref-60">60</a>). Finally, the optimal treatment duration of anticoagulation after 3 to 6 months for patients with CAT remains unanswered. <a href="#T3">Table 3</a> summarizes the characteristics of the available DOAC.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Characteristics of direct oral anticoagulants used or being investigated in patients with cancer.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d37824e971 class=n-a></a><thead><a name=d37824e973 class=n-a></a><tr><a name=d37824e975 class=n-a></a><th colspan=1 rowspan=1><a name=d37824e977 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e979 class=n-a></a>Dabigatran</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e982 class=n-a></a>Rivaroxaban</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e985 class=n-a></a>Apixaban</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e988 class=n-a></a>Edoxaban</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e992 class=n-a></a>LMWH</th></tr></thead><tbody><a name=d37824e997 class=n-a></a><tr><a name=d37824e999 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1001 class=n-a></a>Target</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1004 class=n-a></a>FIIa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1007 class=n-a></a>FXa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1010 class=n-a></a>FXa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1013 class=n-a></a>FXa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1017 class=n-a></a>Indirect FXa/FIIa</td></tr><tr><a name=d37824e1021 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1023 class=n-a></a>Prodrug</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1026 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1029 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1032 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1035 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1039 class=n-a></a>No</td></tr><tr><a name=d37824e1043 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1045 class=n-a></a>Bioavailability</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1048 class=n-a></a>3–7% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1051 class=n-a></a>10 mg dose: 100%<br class=br>20 mg dose:<br class=br>100% when taken<br class=br>together with food;<br class=br>66% under fasting<br class=br>conditions<br class=br><br class=br>Inter-individual<br class=br>variability: 30–40%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1070 class=n-a></a>~50%<br class=br><br class=br><br class=br><br class=br><br class=br><br class=br><br class=br>Inter-individual<br class=br>variability: 30%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1083 class=n-a></a>~62%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1087 class=n-a></a>90–98% Subcutaneous</td></tr><tr><a name=d37824e1091 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1093 class=n-a></a>Renal excretion<br class=br>(percentage of administered<br class=br>dose)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1100 class=n-a></a>5% (4% unchanged)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1103 class=n-a></a>66% (33%<br class=br>unchanged)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1108 class=n-a></a>27% (22%<br class=br>unchanged)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1113 class=n-a></a>35% (24%<br class=br>unchanged)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1119 class=n-a></a>High</td></tr><tr><a name=d37824e1123 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1125 class=n-a></a>Biliary-fecal excretion<br class=br>(percentage of administered<br class=br>dose)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1132 class=n-a></a>95%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1135 class=n-a></a>34%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1138 class=n-a></a>56%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1141 class=n-a></a>62%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1145 class=n-a></a>Low</td></tr><tr><a name=d37824e1150 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1152 class=n-a></a>Metabolism</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1155 class=n-a></a>Glucuronidation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1158 class=n-a></a>CYP3A4 (75%) &gt;<br class=br>CYP2j2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1163 class=n-a></a>CYP3A4 (50%) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1166 class=n-a></a>Hydrolysis &gt;<br class=br>CYP3A4 (27%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1172 class=n-a></a>Desulphation,<br class=br>Depolymerization (&lt;10%)</td></tr><tr><a name=d37824e1178 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1180 class=n-a></a>Interaction with P-glycoprotein<br class=br>inducers/inhibitors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1185 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1188 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1191 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1194 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1198 class=n-a></a>No</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d37824e1206 class=n-a></a><p id=d37824e1208> LMWH, low-molecular-weight heparin.</p></div></div></div><div class=section><a name=d37824e1214 class=n-a></a><h3 class=section-title>Special considerations in patients with cancer</h3><p class="" id=d37824e1219>Vomiting and diarrhea are side effects of cancer treatment and can limit absorption. Changes related to inflammation and collection of extra-vascular fluids can affect distribution of the DOAC. Similarly, changes in body composition, such as reduced lean body mass, a common occurrence in elderly patients with cancer, reduce the distribution volume and increase the risk of acute toxicity, particularly when combined with anti-cancer therapy<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. Decreased lean body mass can also result in an overestimation of renal function, which can put the patient at risk of over-anticoagulation<sup><a href="#ref-58">58</a></sup>. Thrombocytopenia, common in patients with cancer, is also a bleeding concern. Metabolism through the cytochrome P450 is altered in cancer, and there is large inter-individual variability in CYP3A activity in patients with cancer<sup><a href="#ref-63">63</a></sup>, further complicating attempts to predict the potential clinical impact of specific drug–drug interactions. Altered hepatic function and inflammatory responses have been proposed as an underlying mechanism for a decrease in drug metabolism through the CYP system in patients with cancer<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. Furthermore, these patients are typically on multiple medications, increasing the risk of drug–drug interactions. Thus, anticoagulant pharmacokinetics can be widely variable across patients with cancer, rendering prediction of the dose-response relationship difficult. Overall, patients with cancer tend to be elderly, receive multiple concomitant drug therapies, and are more likely to have some degree of hepatic or renal insufficiency.</p></div><div class=section><a name=d37824e1245 class=n-a></a><h3 class=section-title>Renal and hepatic impairment</h3><p class="" id=d37824e1250>About 60% of patients with cancer have decreased renal function<sup><a href="#ref-66">66</a></sup> and this decline is sometimes sudden. Major or fatal bleeding can occur following a rapid decline in renal function in patients on anticoagulants. Renal and hepatic impairment will affect the plasma levels of the different DOACs on the basis of their respective mechanisms of elimination<sup><a href="#ref-67">67</a></sup>. Moderate hepatic impairment (Child–Pugh B) increases plasma levels of rivaroxaban only (127%). There are no data on severe hepatic impairment.</p></div><div class=section><a name=d37824e1263 class=n-a></a><h3 class=section-title>Thrombocytopenia</h3><p class="" id=d37824e1268>Thrombocytopenia can develop directly from tumor invasion of bone marrow, as a result of secondary immune-mediated responses, or following myeloablative chemotherapy<sup><a href="#ref-60">60</a></sup>. In patients with cancer and thrombocytopenia, the risk of bleeding is increased. Full doses of anticoagulant can be used for the treatment of established CAT if the platelet count is above 50 G/L and bleeding is not evident; for patients with a platelet count below 50 G/L, decisions about treatment and dose should be made on a case-by-case basis<sup><a href="#ref-11">11</a></sup> and available data do not support one management strategy over another (LMWH or DOAC).</p></div><div class=section><a name=d37824e1280 class=n-a></a><h3 class=section-title>Drug–drug interactions</h3><p class="" id=d37824e1285>Drugs that significantly induce or inhibit CYP3A4, a member of the hepatic cytochrome P450 enzyme system, or ATP-binding cassette transporters, such as P-gp and breast cancer–resistant protein (BCRP), can change the plasma concentration of DOACs (reviewed in <a href="#ref-59">59</a>,<a href="#ref-67">67</a>,<a href="#ref-68">68</a>). Limited studies have documented the effects of co-administration of DOACs and strong inhibitors and inducers of CYP3A4 and P-gp<sup><a href="#ref-67">67</a></sup>.</p><p class="" id=d37824e1301>All DOACs undergo an efflux transport mainly via P-gp, meditating drug absorption and excretion. Altered P-gp function is one mechanism of chemotherapy resistance, in which its activity limits absorption of the chemotherapy agent into malignant cells<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>. This pharmacodynamic profile suggests that inhibitors or inducers of P-gp can lead to over- or under-anticoagulation. However, this theoretical risk is difficult to predict given the wide inter-individual variability on P-gp activity<sup><a href="#ref-71">71</a></sup>. Rivaroxaban and apixaban are both substrates of CYP3A4 and therefore susceptible to changes in plasma concentrations when given concomitantly with drugs that induce or inhibit CYP3A4<sup><a href="#ref-67">67</a></sup>. Rivaroxaban and apixaban are also substrates of BCRP.</p><p class="" id=d37824e1319>For all of the DOACs, concomitant administration of rifampicin, a strong inducer of CYP3A4 and P-gp, produces clinically important decreases in DOAC plasma concentrations and increases the risk of thrombosis<sup><a href="#ref-72">72</a>–<a href="#ref-74">74</a></sup>. The product monographs for all of the DOACs indicate that concomitant administration with the CYP3A4 and P-gp inducers rifampicin, carbamazepine, and phenytoin and also phenobarbital in the case of apixaban, edoxaban, and rivaroxaban should be carried out with caution or avoided<sup><a href="#ref-75">75</a>–<a href="#ref-78">78</a></sup>.</p></div><div class=section><a name=d37824e1337 class=n-a></a><h3 class=section-title>DOAC drug–drug interaction with cancer therapies</h3><p class="" id=d37824e1342>DOAC absorption can be altered by cancer treatments such as surgery and radiotherapy<sup><a href="#ref-58">58</a></sup>. The concomitant administration of DOACs with anti-cancer and adjunctive pharmacotherapies that are inhibitors or inducers of Pg-P and CYP3A4 poses a theoretical risk of VTE or bleeding by pushing circulating DOAC levels outside the therapeutic range. Direct studies on interactions between DOAC and anti-cancer therapies are not available. Certain chemotherapies, hormone therapies, and targeted therapies, such as tyrosine kinase inhibitors, are potent CYP inducers or inhibitors. Some anti-cancer treatments can also induce or inhibit P-gp. Potential interactions have been compiled (reviewed in <a href="#ref-58">58</a>–<a href="#ref-60">60</a>,<a href="#ref-79">79</a>) and are summarized in <a href="#T4">Table 4</a>.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Anti-cancer treatments predicted to affect direct oral anticoagulant plasma levels through moderate to strong interaction with CYP3A4 or P-glycoprotein or both.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d37824e1372 class=n-a></a><thead><a name=d37824e1374 class=n-a></a><tr><a name=d37824e1376 class=n-a></a><th colspan=1 rowspan=1><a name=d37824e1378 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e1380 class=n-a></a>CYP3A4</th><th align=left colspan=1 rowspan=1 valign=top><a name=d37824e1383 class=n-a></a>P-glycoprotein</th></tr></thead><tbody><a name=d37824e1388 class=n-a></a><tr><a name=d37824e1390 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1392 class=n-a></a>Inducers</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1395 class=n-a></a>Antimitotic agents: paclitaxel, ifosfamide, mitotane<br class=br>Tyrosine kinase inhibitors: vemurafenib, dabrafenib,<br class=br>vemurafenib<br class=br>Hormone therapy: enzalutamide<br class=br>Immunomodulators: dexamethasone, prednisone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1406 class=n-a></a>Antimitotic agents: vinblastine<br class=br>Anthracyclines/anthracenediones: doxorubicin<br class=br>Tyrosine kinase inhibitors: vandetanib, sunitinib<br class=br>Immunomodulators: dexamethasone</td></tr><tr><a name=d37824e1416 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1418 class=n-a></a>Inhibitors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1421 class=n-a></a>Tyrosine kinase inhibitors: imatinib, crizotinib, idelalisib,<br class=br>lapatinib, nilotinib<br class=br>Hormone therapy: bicalutamide, abiraterone<br class=br>Immunomodulators: cyclosporine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1430 class=n-a></a>Tyrosine kinase inhibitors: imatinib, crizotinib, nilotinib, lapatinib,<br class=br>Hormone therapy: abiraterone, tamoxifen, enzalutamide,<br class=br>Immunomodulators: tacrolimus, cyclosporine, </td></tr><tr><a name=d37824e1438 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1440 class=n-a></a>Substrates</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1443 class=n-a></a>Antimitotic agents: paclitaxel, docetaxel, vinblastine,<br class=br>vincristine, vinorelbine<br class=br>Topoisomerase inhibitors: etoposide, irinotecan<br class=br>Anthracyclines/anthracenediones:<br class=br>doxorubicin<br class=br>Alkylating agents:<br class=br>ifosfamide, busulfan<br class=br>Tyrosine kinase inhibitors: crizotinib, imatinib, dasatinib,<br class=br>nilotinib, erlotinib, gefitinib, lapatinib, sunitinib, vandetanib<br class=br>Monoclonal antibodies: brentuximab<br class=br>Hormone therapy: abiraterone, enzalutamide, tamoxifen,<br class=br>flutamide<br class=br>Immunomodulators: cyclosporine , dexamethasone,<br class=br>sirolimus, everolimus, temsirolimus, tacrolimus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d37824e1474 class=n-a></a>Antimitotic agents: paclitaxel, vinblastine, vincristine, docetaxel<br class=br>Antimetabolites: methotrexate<br class=br>Topoisomerase inhibitors: irinotecan, etoposide<br class=br>Anthracyclines/anthracenediones: doxorubicin, daunorubicin,<br class=br>idarubicin<br class=br>Alkylating agents: bendamustine<br class=br>Intercalating agents: mitomycin C<br class=br>Tyrosine kinase inhibitors: imatinib, nilotinib, lapatinib, crizotinib,<br class=br>vemurafenib<br class=br>Immunomodulators: cyclosporine, sirolimus, everolimus,<br class=br>temsirolimus, tacrolimus, dexamethasone</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d37824e1503 class=n-a></a><p id=d37824e1505> Adapted from<sup><a href="#ref-58">58</a>–<a href="#ref-60">60</a>,<a href="#ref-68">68</a>,<a href="#ref-79">79</a></sup>.</p></div></div></div></div><div class=section><a name=d37824e1525 class=n-a></a><h3 class=section-title>Treatment duration for established CAT</h3><p class="" id=d37824e1530>Determining the optimal duration of anticoagulation in the treatment of established CAT remains an unresolved issue. RCTs that compared LMWH with VKA for the treatment of acute VTE in this setting followed the participants for only 3 to 6 months<sup><a href="#ref-12">12</a>–<a href="#ref-16">16</a></sup>. Since the risk of recurrent VTE remains high as long as the cancer is active, extended duration of anticoagulant therapy is usually proposed despite the lack of evidence from RCTs as long as specific anti-cancer treatments, classically defined by the use of anti-cancer surgery, chemotherapy, radiotherapy, and growth factors, are being delivered<sup><a href="#ref-11">11</a></sup>. Data are still insufficient to evaluate the specific VTE risk associated with long-term immunotherapy.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d37824e1548>Conclusions</h2><p class="" id=d37824e1551>New dedicated clinical trial evidence showing an efficacy of DOAC that is similar to or better than LMWH in the treatment and secondary prevention of CAT offers a new treatment option to patients with cancer. However, increased bleeding risks compared with LMWH, particularly in GI and genitourinary cancers, indicate a need for caution. Administering DOACs to cancer patients with CAT will necessitate individualized treatment decisions that consider patient characteristics, co-morbidities, and the potential for drug–drug interactions. Primary prophylaxis in ambulatory cancer patients initiating chemotherapy remains an area of uncertainty. The incorporation of VTE risk assessment models into clinical trial designs to stratify patients according to VTE risk may help identify cancer patients likely to benefit from primary VTE prophylaxis. The two recent trials assessing the safety and efficacy of DOACs in the prevention of VTE included patients with a Khorana score of at least 2 and reported a significant reduction in the rates of VTE, but the trial investigating apixaban reported increased bleeding risk. Future studies will continue to clarify which patients with cancer should receive primary thromboprophylaxis and the safety profiles of the different DOACs in this clinical setting.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d37824e1 class=n-a></a><h2 class=main-title id=d38084>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d37824e1558 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d38337>References</h2><div class="section ref-list"><a name=d37824e1558 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d37824e1565 class=n-a></a>Chew HK, Wun T, Harvey D, <i> et al.</i>: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. <i>Arch Intern Med.</i> 2006; <b>166</b>(4): 458–64. <a target=xrefwindow id=d37824e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/16505267">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1579 href="https://doi.org/10.1001/archinte.166.4.458">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d37824e1588 class=n-a></a>Khorana AA, Francis CW, Culakova E, <i> et al.</i>: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>J Thromb Haemost.</i> 2007; <b>5</b>(3): 632–4. <a target=xrefwindow id=d37824e1599 href="http://www.ncbi.nlm.nih.gov/pubmed/17319909">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1602 href="https://doi.org/10.1111/j.1538-7836.2007.02374.x">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d37824e1611 class=n-a></a>Walker AJ, Card TR, West J, <i> et al.</i>: Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. <i>Eur J Cancer.</i> 2013; <b>49</b>(6): 1404–13. <a target=xrefwindow id=d37824e1622 href="http://www.ncbi.nlm.nih.gov/pubmed/23146958">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1625 href="https://doi.org/10.1016/j.ejca.2012.10.021">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5232956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e1634 class=n-a></a>Cronin-Fenton DP, Søndergaard F, Pedersen LA, <i> et al.</i>: Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. <i>Br J Cancer.</i> 2010; <b>103</b>(7): 947–53. <a target=xrefwindow id=d37824e1645 href="http://www.ncbi.nlm.nih.gov/pubmed/20842120">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1648 href="https://doi.org/10.1038/sj.bjc.6605883">Publisher Full Text </a> | <a target=xrefwindow id=d37824e1652 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2965880">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5232956">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d37824e1665 class=n-a></a>Heit JA, Spencer FA, White RH: The epidemiology of venous thromboembolism. <i>J Thromb Thrombolysis.</i> 2016; <b>41</b>(1): 3–14. <a target=xrefwindow id=d37824e1673 href="http://www.ncbi.nlm.nih.gov/pubmed/26780736">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1676 href="https://doi.org/10.1007/s11239-015-1311-6">Publisher Full Text </a> | <a target=xrefwindow id=d37824e1679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4715842">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d37824e1689 class=n-a></a>van Es N, Bleker SM, Di Nisio M: Cancer-associated unsuspected pulmonary embolism. <i>Thromb Res.</i> 2014; <b>133 Suppl 2</b>: S172–S178. <a target=xrefwindow id=d37824e1697 href="http://www.ncbi.nlm.nih.gov/pubmed/24862140">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1700 href="https://doi.org/10.1016/S0049-3848(14)50028-X">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d37824e1709 class=n-a></a>Timp JF, Braekkan SK, Versteeg HH, <i> et al.</i>: Epidemiology of cancer-associated venous thrombosis. <i>Blood.</i> 2013; <b>122</b>(10): 1712–23. <a target=xrefwindow id=d37824e1720 href="http://www.ncbi.nlm.nih.gov/pubmed/23908465">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1723 href="https://doi.org/10.1182/blood-2013-04-460121">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d37824e1732 class=n-a></a>Prandoni P, Lensing AW, Piccioli A, <i> et al.</i>: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. <i>Blood.</i> 2002; <b>100</b>(10): 3484–8. <a target=xrefwindow id=d37824e1743 href="http://www.ncbi.nlm.nih.gov/pubmed/12393647">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1746 href="https://doi.org/10.1182/blood-2002-01-0108">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d37824e1755 class=n-a></a>Kamphuisen PW, Beyer-Westendorf J: Bleeding complications during anticoagulant treatment in patients with cancer. <i>Thromb Res.</i> 2014; <b>133 Suppl 2</b>: S49–S55. <a target=xrefwindow id=d37824e1763 href="http://www.ncbi.nlm.nih.gov/pubmed/24862146">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1766 href="https://doi.org/10.1016/S0049-3848(14)50009-6">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d37824e1775 class=n-a></a>Caine GJ, Stonelake PS, Lip GY, <i> et al.</i>: The hypercoagulable state of malignancy: pathogenesis and current debate. <i>Neoplasia.</i> 2002; <b>4</b>(6): 465–73. <a target=xrefwindow id=d37824e1786 href="http://www.ncbi.nlm.nih.gov/pubmed/12407439">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1789 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1550339">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d37824e1798 class=n-a></a>Farge D, Bounameaux H, Brenner B, <i> et al.</i>: International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncol.</i> 2016; <b>17</b>(10): e452–e466. <a target=xrefwindow id=d37824e1809 href="http://www.ncbi.nlm.nih.gov/pubmed/27733271">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1812 href="https://doi.org/10.1016/S1470-2045(16)30369-2">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734096555"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e1822 class=n-a></a>Meyer G, Besse B, Doubre H, <i> et al.</i>: Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. <i>Eur Respir J.</i> 2018; <b>52</b>(4): pii: 1801220. <a target=xrefwindow id=d37824e1833 href="http://www.ncbi.nlm.nih.gov/pubmed/30262574">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1836 href="https://doi.org/10.1183/13993003.01220-2018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734096555">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d37824e1849 class=n-a></a>Lee AY, Levine MN, Baker RI, <i> et al.</i>: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. <i>N Engl J Med.</i> 2003; <b>349</b>(2): 146–53. <a target=xrefwindow id=d37824e1860 href="http://www.ncbi.nlm.nih.gov/pubmed/12853587">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1863 href="https://doi.org/10.1056/NEJMoa025313">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d37824e1872 class=n-a></a>Hull RD, Pineo GF, Brant RF, <i> et al.</i>: Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. <i>Am J Med.</i> 2006; <b>119</b>(12): 1062–72. <a target=xrefwindow id=d37824e1883 href="http://www.ncbi.nlm.nih.gov/pubmed/17145251">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1886 href="https://doi.org/10.1016/j.amjmed.2006.02.022">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735380543"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e1895 class=n-a></a>Deitcher SR, Kessler CM, Merli G, <i> et al.</i>: Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. <i>Clin Appl Thromb Hemost.</i> 2006; <b>12</b>(4): 389–96. <a target=xrefwindow id=d37824e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/17000884">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1909 href="https://doi.org/10.1177/1076029606293692">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735380543">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d37824e1922 class=n-a></a>Lee AYY, Kamphuisen PW, Meyer G, <i> et al.</i>: Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. <i>JAMA.</i> 2015; <b>314</b>(7): 677–86. <a target=xrefwindow id=d37824e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/26284719">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1936 href="https://doi.org/10.1001/jama.2015.9243">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d37824e1945 class=n-a></a>Watson HG, Keeling DM, Laffan M, <i> et al.</i>: Guideline on aspects of cancer-related venous thrombosis. <i>Br J Haematol.</i> 2015; <b>170</b>(5): 640–8. <a target=xrefwindow id=d37824e1956 href="http://www.ncbi.nlm.nih.gov/pubmed/26114207">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1959 href="https://doi.org/10.1111/bjh.13556">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d37824e1969 class=n-a></a>Easaw JC, Shea-Budgell MA, Wu CM, <i> et al.</i>: Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. <i>Curr Oncol.</i> 2015; <b>22</b>(2): 133–43. <a target=xrefwindow id=d37824e1980 href="http://www.ncbi.nlm.nih.gov/pubmed/25908912">PubMed Abstract </a> | <a target=xrefwindow id=d37824e1983 href="https://doi.org/10.3747/co.22.2586">Publisher Full Text </a> | <a target=xrefwindow id=d37824e1987 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4399610">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d37824e1996 class=n-a></a>Easaw JC, Shea-Budgell MA, Wu CM, <i> et al.</i>: Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. <i>Curr Oncol.</i> 2015; <b>22</b>(2): 144–55. <a target=xrefwindow id=d37824e2007 href="http://www.ncbi.nlm.nih.gov/pubmed/25908913">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2010 href="https://doi.org/10.3747/co.22.2587">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2014 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4399611">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d37824e2023 class=n-a></a>Lyman GH, Khorana AA, Kuderer NM, <i> et al.</i>: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol.</i> 2013; <b>31</b>(17): 2189–204. <a target=xrefwindow id=d37824e2034 href="http://www.ncbi.nlm.nih.gov/pubmed/23669224">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2037 href="https://doi.org/10.1200/JCO.2013.49.1118">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725320626"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2046 class=n-a></a>Lyman GH, Bohlke K, Khorana AA, <i> et al.</i>: Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. <i>J Clin Oncol.</i> 2015; <b>33</b>(6): 654–6. <a target=xrefwindow id=d37824e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/25605844">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2060 href="https://doi.org/10.1200/JCO.2014.59.7351">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2064 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881372">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725320626">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726141242"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2077 class=n-a></a>Kearon C, Akl EA, Ornelas J, <i> et al.</i>: Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest.</i> 2016; <b>149</b>(2): 315–52. <a target=xrefwindow id=d37824e2088 href="http://www.ncbi.nlm.nih.gov/pubmed/26867832">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2091 href="https://doi.org/10.1016/j.chest.2015.11.026">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726141242">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d37824e2104 class=n-a></a>Schulman S, Goldhaber SZ, Kearon C, <i> et al.</i>: Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. <i>Thromb Haemost.</i> 2015; <b>114</b>(1): 150–7. <a target=xrefwindow id=d37824e2115 href="http://www.ncbi.nlm.nih.gov/pubmed/25739680">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2118 href="https://doi.org/10.1160/TH14-11-0977">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d37824e2128 class=n-a></a>Prins MH, Lensing AW, Brighton TA, <i> et al.</i>: Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematol.</i> 2014; <b>1</b>(1): e37–e46. <a target=xrefwindow id=d37824e2139 href="http://www.ncbi.nlm.nih.gov/pubmed/27030066">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2142 href="https://doi.org/10.1016/S2352-3026(14)70018-3">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d37824e2151 class=n-a></a>Agnelli G, Buller HR, Cohen A, <i> et al.</i>: Oral apixaban for the treatment of venous thromboembolism in cancer patients: Results from the AMPLIFY trial. <i>J Thromb Haemost.</i> 2015; <b>13</b>(12): 2187–91. <a target=xrefwindow id=d37824e2162 href="http://www.ncbi.nlm.nih.gov/pubmed/26407753">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2165 href="https://doi.org/10.1111/jth.13153">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726597992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2174 class=n-a></a>Raskob GE, van Es N, Segers A, <i> et al.</i>: Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematol.</i> 2016; <b>3</b>(8): e379–e387. <a target=xrefwindow id=d37824e2185 href="http://www.ncbi.nlm.nih.gov/pubmed/27476789">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2188 href="https://doi.org/10.1016/S2352-3026(16)30057-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726597992">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d37824e2201 class=n-a></a>Carrier M, Cameron C, Delluc A, <i> et al.</i>: Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. <i>Thromb Res.</i> 2014; <b>134</b>(6): 1214–9. <a target=xrefwindow id=d37824e2212 href="http://www.ncbi.nlm.nih.gov/pubmed/25457583">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2215 href="https://doi.org/10.1016/j.thromres.2014.09.039">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d37824e2224 class=n-a></a>van der Hulle T, den Exter PL, Kooiman J, <i> et al.</i>: Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. <i>J Thromb Haemost.</i> 2014; <b>12</b>(7): 1116–20. <a target=xrefwindow id=d37824e2235 href="http://www.ncbi.nlm.nih.gov/pubmed/24819040">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2238 href="https://doi.org/10.1111/jth.12605">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d37824e2247 class=n-a></a>Vedovati MC, Germini F, Agnelli G, <i> et al.</i>: Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. <i>Chest.</i> 2015; <b>147</b>(2): 475–83. <a target=xrefwindow id=d37824e2258 href="http://www.ncbi.nlm.nih.gov/pubmed/25211264">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2261 href="https://doi.org/10.1378/chest.14-0402">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1516961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2271 class=n-a></a>Schulman S, Kearon C, Kakkar AK, <i> et al.</i>: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. <i>N Engl J Med.</i> 2009; <b>361</b>(24): 2342–52. <a target=xrefwindow id=d37824e2282 href="http://www.ncbi.nlm.nih.gov/pubmed/19966341">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2285 href="https://doi.org/10.1056/NEJMoa0906598">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1516961">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d37824e2298 class=n-a></a>Schulman S, Kakkar AK, Goldhaber SZ, <i> et al.</i>: Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. <i>Circulation.</i> 2014; <b>129</b>(7): 764–72. <a target=xrefwindow id=d37824e2309 href="http://www.ncbi.nlm.nih.gov/pubmed/24344086">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2312 href="https://doi.org/10.1161/CIRCULATIONAHA.113.004450">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14259964"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2321 class=n-a></a>EINSTEIN–PE Investigators, Büller HR, Prins MH, <i> et al.</i>: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>N Engl J Med.</i> 2012; <b>366</b>(14): 1287–97. <a target=xrefwindow id=d37824e2332 href="http://www.ncbi.nlm.nih.gov/pubmed/22449293">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2335 href="https://doi.org/10.1056/NEJMoa1113572">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14259964">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9159962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2348 class=n-a></a>EINSTEIN Investigators, Bauersachs R, Berkowitz SD, <i> et al.</i>: Oral rivaroxaban for symptomatic venous thromboembolism. <i>N Engl J Med.</i> 2010; <b>363</b>(26): 2499–510. <a target=xrefwindow id=d37824e2359 href="http://www.ncbi.nlm.nih.gov/pubmed/21128814">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2362 href="https://doi.org/10.1056/NEJMoa1007903">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9159962">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d37824e2375 class=n-a></a>Hokusai-VTE Investigators, Büller HR, Décousus H, <i> et al.</i>: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. <i>N Engl J Med.</i> 2013; <b>369</b>(15): 1406–15. <a target=xrefwindow id=d37824e2386 href="http://www.ncbi.nlm.nih.gov/pubmed/23991658">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2389 href="https://doi.org/10.1056/NEJMoa1306638">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718482057"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2398 class=n-a></a>Agnelli G, Buller HR, Cohen A, <i> et al.</i>: Oral apixaban for the treatment of acute venous thromboembolism. <i>N Engl J Med.</i> 2013; <b>369</b>(9): 799–808. <a target=xrefwindow id=d37824e2409 href="http://www.ncbi.nlm.nih.gov/pubmed/23808982">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2412 href="https://doi.org/10.1056/NEJMoa1302507">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718482057">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732284659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2426 class=n-a></a>Raskob GE, van Es N, Verhamme P, <i> et al.</i>: Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>N Engl J Med.</i> 2018; <b>378</b>(7): 615–24. <a target=xrefwindow id=d37824e2437 href="http://www.ncbi.nlm.nih.gov/pubmed/29231094">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2440 href="https://doi.org/10.1056/NEJMoa1711948">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732284659">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733213416"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2453 class=n-a></a>Young AM, Marshall A, Thirlwall J, <i> et al.</i>: Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). <i>J Clin Oncol.</i> 2018; <b>36</b>(20): 2017–23. <a target=xrefwindow id=d37824e2464 href="http://www.ncbi.nlm.nih.gov/pubmed/29746227">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2467 href="https://doi.org/10.1200/JCO.2018.78.8034">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733213416">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d37824e2480 class=n-a></a>McBane RD, Wysokinski WE, Le-Rademacher J, <i> et al.</i>: Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial. <i>Blood.</i> 2018; <b>132</b>(Suppl 1): 421. <a target=xrefwindow id=d37824e2491 href="http://www.bloodjournal.org/content/132/Suppl_1/421?sso-checked=true">Reference Source</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735124368"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2500 class=n-a></a>Khorana AA, Soff GA, Kakkar AK, <i> et al.</i>: Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>N Engl J Med.</i> 2019; <b>380</b>(8): 720–8. <a target=xrefwindow id=d37824e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/30786186">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2514 href="https://doi.org/10.1056/NEJMoa1814630">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735124368">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734552032"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2527 class=n-a></a>Carrier M, Abou-Nassar K, Mallick R, <i> et al.</i>: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>N Engl J Med.</i> 2019; <b>380</b>(8): 711–9. <a target=xrefwindow id=d37824e2538 href="http://www.ncbi.nlm.nih.gov/pubmed/30511879">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2541 href="https://doi.org/10.1056/NEJMoa1814468">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734552032">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d37824e2554 class=n-a></a>Cajfinger F, Debourdeau P, Lamblin A, <i> et al.</i>: Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. <i>Thromb Res.</i> 2016; <b>144</b>: 85–92. <a target=xrefwindow id=d37824e2565 href="http://www.ncbi.nlm.nih.gov/pubmed/27318244">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2568 href="https://doi.org/10.1016/j.thromres.2016.06.005">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d37824e2578 class=n-a></a>Farge D, Cajfinger F, Falvo N, <i> et al.</i>: Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). <i>Oncotarget.</i> 2018; <b>9</b>(43): 26990–26999. <a target=xrefwindow id=d37824e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/29930745">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2592 href="https://doi.org/10.18632/oncotarget.25454">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2596 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6007467">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d37824e2605 class=n-a></a>Vanassche T, Hirsh J, Eikelboom JW, <i> et al.</i>: Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thromb Haemost.</i> 2014; <b>112</b>(5): 918–23. <a target=xrefwindow id=d37824e2616 href="http://www.ncbi.nlm.nih.gov/pubmed/25187203">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2619 href="https://doi.org/10.1160/TH14-04-0346">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d37824e2628 class=n-a></a>Spencer FA, Lessard D, Emery C, <i> et al.</i>: Venous thromboembolism in the outpatient setting. <i>Arch Intern Med.</i> 2007; <b>167</b>(14): 1471–5. <a target=xrefwindow id=d37824e2639 href="http://www.ncbi.nlm.nih.gov/pubmed/17646600">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2642 href="https://doi.org/10.1001/archinte.167.14.1471">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2646 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2762787">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d37824e2655 class=n-a></a>Agnelli G, George DJ, Kakkar AK, <i> et al.</i>: Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(7): 601–9. <a target=xrefwindow id=d37824e2666 href="http://www.ncbi.nlm.nih.gov/pubmed/22335737">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2669 href="https://doi.org/10.1056/NEJMoa1108898">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d37824e2678 class=n-a></a>Agnelli G, Gussoni G, Bianchini C, <i> et al.</i>: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncol.</i> 2009; <b>10</b>(10): 943–9. <a target=xrefwindow id=d37824e2689 href="http://www.ncbi.nlm.nih.gov/pubmed/19726226">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2692 href="https://doi.org/10.1016/S1470-2045(09)70232-3">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727052988"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2701 class=n-a></a>Di Nisio M, Porreca E, Candeloro M, <i> et al.</i>: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. <i>Cochrane Database Syst Rev.</i> 2016; <b>12</b>: CD008500. <a target=xrefwindow id=d37824e2712 href="http://www.ncbi.nlm.nih.gov/pubmed/27906452">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2715 href="https://doi.org/10.1002/14651858.CD008500.pub4">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2719 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6463937">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727052988">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d37824e2733 class=n-a></a>Maraveyas A, Waters J, Roy R, <i> et al.</i>: Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. <i>Eur J Cancer.</i> 2012; <b>48</b>(9): 1283–92. <a target=xrefwindow id=d37824e2744 href="http://www.ncbi.nlm.nih.gov/pubmed/22100906">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2747 href="https://doi.org/10.1016/j.ejca.2011.10.017">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d37824e2756 class=n-a></a>Pelzer U, Opitz B, Deutschinoff G, <i> et al.</i>: Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(18): 2028–34. <a target=xrefwindow id=d37824e2767 href="http://www.ncbi.nlm.nih.gov/pubmed/25987694">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2770 href="https://doi.org/10.1200/JCO.2014.55.1481">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d37824e2779 class=n-a></a>Khorana AA, Kuderer NM, Culakova E, <i> et al.</i>: Development and validation of a predictive model for chemotherapy-associated thrombosis. <i>Blood.</i> 2008; <b>111</b>(10): 4902–7. <a target=xrefwindow id=d37824e2790 href="http://www.ncbi.nlm.nih.gov/pubmed/18216292">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2793 href="https://doi.org/10.1182/blood-2007-10-116327">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2797 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2384124">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d37824e2806 class=n-a></a>Ay C, Dunkler D, Marosi C, <i> et al.</i>: Prediction of venous thromboembolism in cancer patients. <i>Blood.</i> 2010; <b>116</b>(24): 5377–82. <a target=xrefwindow id=d37824e2817 href="http://www.ncbi.nlm.nih.gov/pubmed/20829374">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2820 href="https://doi.org/10.1182/blood-2010-02-270116">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727658169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2829 class=n-a></a>van Es N, Di Nisio M, Cesarman G, <i> et al.</i>: Comparison of risk prediction scores for venous thromboembolism in cancer patients: A prospective cohort study. <i>Haematologica.</i> 2017; <b>102</b>(9): 1494–501. <a target=xrefwindow id=d37824e2840 href="http://www.ncbi.nlm.nih.gov/pubmed/28550192">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2843 href="https://doi.org/10.3324/haematol.2017.169060">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2847 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5685240">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727658169">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726407831"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2860 class=n-a></a>Mansfield AS, Tafur AJ, Wang CE, <i> et al.</i>: Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer. <i>J Thromb Haemost.</i> 2016; <b>14</b>(9): 1773–8. <a target=xrefwindow id=d37824e2871 href="http://www.ncbi.nlm.nih.gov/pubmed/27273134">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2874 href="https://doi.org/10.1111/jth.13378">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2878 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5035574">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726407831">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727537260"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2892 class=n-a></a>Bezan A, Posch F, Ploner F, <i> et al.</i>: Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. <i>PLoS One.</i> 2017; <b>12</b>(4): e0176283. <a target=xrefwindow id=d37824e2903 href="http://www.ncbi.nlm.nih.gov/pubmed/28430804">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2906 href="https://doi.org/10.1371/journal.pone.0176283">Publisher Full Text </a> | <a target=xrefwindow id=d37824e2910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5400272">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727537260">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d37824e2923 class=n-a></a>Verso M, Agnelli G, Barni S, <i> et al.</i>: A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. <i>Intern Emerg Med.</i> 2012; <b>7</b>(3): 291–2. <a target=xrefwindow id=d37824e2934 href="http://www.ncbi.nlm.nih.gov/pubmed/22547369">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2937 href="https://doi.org/10.1007/s11739-012-0784-y">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733846395"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2946 class=n-a></a>Pabinger I, van Es N, Heinze G, <i> et al.</i>: A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts. <i>Lancet Haematol.</i> 2018; <b>5</b>(7): e289–e298. <a target=xrefwindow id=d37824e2957 href="http://www.ncbi.nlm.nih.gov/pubmed/29885940">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2960 href="https://doi.org/10.1016/S2352-3026(18)30063-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733846395">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735126584"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2973 class=n-a></a>Agnelli G: Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. <i>N Engl J Med.</i> 2019; <b>380</b>(8): 781–3. <a target=xrefwindow id=d37824e2981 href="http://www.ncbi.nlm.nih.gov/pubmed/30786193">PubMed Abstract </a> | <a target=xrefwindow id=d37824e2984 href="https://doi.org/10.1056/NEJMe1816060">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735126584">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733897107"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e2997 class=n-a></a>Bellesoeur A, Thomas-Schoemann A, Allard M, <i> et al.</i>: Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. <i>Crit Rev Oncol Hematol.</i> 2018; <b>129</b>: 102–12. <a target=xrefwindow id=d37824e3008 href="http://www.ncbi.nlm.nih.gov/pubmed/30097228">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3011 href="https://doi.org/10.1016/j.critrevonc.2018.06.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733897107">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d37824e3024 class=n-a></a>Short NJ, Connors JM: New oral anticoagulants and the cancer patient. <i>Oncologist.</i> 2014; <b>19</b>(1): 82–93. <a target=xrefwindow id=d37824e3032 href="http://www.ncbi.nlm.nih.gov/pubmed/24319019">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3035 href="https://doi.org/10.1634/theoncologist.2013-0239">Publisher Full Text </a> | <a target=xrefwindow id=d37824e3038 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3903061">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735393006"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e3048 class=n-a></a>Mosarla RC, Vaduganathan M, Qamar A, <i> et al.</i>: Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. <i>J Am Coll Cardiol.</i> 2019; <b>73</b>(11): 1336–49. <a target=xrefwindow id=d37824e3059 href="http://www.ncbi.nlm.nih.gov/pubmed/30898209">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3062 href="https://doi.org/10.1016/j.jacc.2019.01.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735393006">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726912896"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e3075 class=n-a></a>Bigot F, Boudou-Rouquette P, Arrondeau J, <i> et al.</i>: Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Invest New Drugs.</i> 2017; <b>35</b>(2): 242–6. <a target=xrefwindow id=d37824e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/27796680">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3089 href="https://doi.org/10.1007/s10637-016-0400-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726912896">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d37824e3102 class=n-a></a>Huillard O, Mir O, Peyromaure M, <i> et al.</i>: Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. <i>Br J Cancer.</i> 2013; <b>108</b>(5): 1034–41. <a target=xrefwindow id=d37824e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/23462722">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3116 href="https://doi.org/10.1038/bjc.2013.58">Publisher Full Text </a> | <a target=xrefwindow id=d37824e3120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3619075">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d37824e3129 class=n-a></a>Baker SD, van Schaik RH, Rivory LP, <i> et al.</i>: Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clin Cancer Res.</i> 2004; <b>10</b>(24): 8341–50. <a target=xrefwindow id=d37824e3140 href="http://www.ncbi.nlm.nih.gov/pubmed/15623611">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3143 href="https://doi.org/10.1158/1078-0432.CCR-04-1371">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d37824e3152 class=n-a></a>Shedlofsky SI, Israel BC, McClain CJ, <i> et al.</i>: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. <i>J Clin Invest.</i> 1994; <b>94</b>(6): 2209–14. <a target=xrefwindow id=d37824e3163 href="http://www.ncbi.nlm.nih.gov/pubmed/7989576 ">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3166 href="https://doi.org/10.1172/JCI117582">Publisher Full Text </a> | <a target=xrefwindow id=d37824e3170 href="http://www.ncbi.nlm.nih.gov/pmc/articles/330046">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d37824e3179 class=n-a></a>Slaviero KA, Clarke SJ, Rivory LP: Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. <i>Lancet Oncol.</i> 2003; <b>4</b>(4): 224–32. <a target=xrefwindow id=d37824e3187 href="http://www.ncbi.nlm.nih.gov/pubmed/12681266">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3190 href="https://doi.org/10.1016/S1470-2045(03)01034-9">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d37824e3200 class=n-a></a>Launay-Vacher V, Janus N, Deray G: Renal insufficiency and cancer treatments. <i>ESMO Open.</i> 2016; <b>1</b>(4): e000091. <a target=xrefwindow id=d37824e3208 href="http://www.ncbi.nlm.nih.gov/pubmed/27843635">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3211 href="https://doi.org/10.1136/esmoopen-2016-000091">Publisher Full Text </a> | <a target=xrefwindow id=d37824e3214 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5070272">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726469201"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e3223 class=n-a></a>Bertoletti L, Ollier E, Duvillard C, <i> et al.</i>: Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. <i>Pharmacol Res.</i> 2017; <b>118</b>: 33–42. <a target=xrefwindow id=d37824e3234 href="http://www.ncbi.nlm.nih.gov/pubmed/27350265">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3237 href="https://doi.org/10.1016/j.phrs.2016.06.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726469201">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735105106"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e3250 class=n-a></a>Riess H, Prandoni P, Harder S, <i> et al.</i>: Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. <i>Crit Rev Oncol Hematol.</i> 2018; <b>132</b>: 169–79. <a target=xrefwindow id=d37824e3261 href="http://www.ncbi.nlm.nih.gov/pubmed/30447923">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3264 href="https://doi.org/10.1016/j.critrevonc.2018.09.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735105106">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d37824e3277 class=n-a></a>Chien AJ, Moasser MM: Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. <i>Semin Oncol.</i> 2008; <b>35</b>(2 Suppl 2): S1–S14; quiz S39. <a target=xrefwindow id=d37824e3285 href="http://www.ncbi.nlm.nih.gov/pubmed/18410794">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3288 href="https://doi.org/10.1053/j.seminoncol.2008.02.010">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d37824e3297 class=n-a></a>Wu CP, Hsieh CH, Wu YS: The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. <i>Mol Pharm.</i> 2011; <b>8</b>(6): 1996–2011. <a target=xrefwindow id=d37824e3305 href="http://www.ncbi.nlm.nih.gov/pubmed/21770407">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3308 href="https://doi.org/10.1021/mp200261n">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d37824e3317 class=n-a></a>Fitzgerald JL, Howes LG: Drug Interactions of Direct-Acting Oral Anticoagulants. <i>Drug Saf.</i> 2016; <b>39</b>(9): 841–5. <a target=xrefwindow id=d37824e3325 href="http://www.ncbi.nlm.nih.gov/pubmed/27435452">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3328 href="https://doi.org/10.1007/s40264-016-0443-8">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d37824e3338 class=n-a></a>Mendell J, Chen S, He L, <i> et al.</i>: The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. <i>Clin Drug Investig.</i> 2015; <b>35</b>(7): 447–53. <a target=xrefwindow id=d37824e3349 href="http://www.ncbi.nlm.nih.gov/pubmed/26068927">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3352 href="https://doi.org/10.1007/s40261-015-0298-2">Publisher Full Text </a> | <a target=xrefwindow id=d37824e3356 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4488474">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d37824e3365 class=n-a></a>Vakkalagadda B, Frost C, Byon W, <i> et al.</i>: Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. <i>Am J Cardiovasc Drugs.</i> 2016; <b>16</b>(2): 119–27. <a target=xrefwindow id=d37824e3376 href="http://www.ncbi.nlm.nih.gov/pubmed/26749408">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3379 href="https://doi.org/10.1007/s40256-015-0157-9">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d37824e3388 class=n-a></a>Härtter S, Koenen-Bergmann M, Sharma A, <i> et al.</i>: Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. <i>Br J Clin Pharmacol.</i> 2012; <b>74</b>(3): 490–500. <a target=xrefwindow id=d37824e3399 href="http://www.ncbi.nlm.nih.gov/pubmed/22348256">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3402 href="https://doi.org/10.1111/j.1365-2125.2012.04218.x">Publisher Full Text </a> | <a target=xrefwindow id=d37824e3406 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3477350">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d37824e3415 class=n-a></a>Bayer: Xarelto Product Monograph 2018. <a target=xrefwindow id=d37824e3417 href="https://www.bayer.ca/omr/online/xarelto-pm-en.pdf">Reference Source</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d37824e3426 class=n-a></a>Servier: LIXIANA Product monograph 2017. <a target=xrefwindow id=d37824e3428 href="https://www.servier.ca/sites/default/files/webform/products/PM_Lixiana_%2026%20JUL%202017%20EN.pdf?ts=1537244353">Reference Source</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d37824e3437 class=n-a></a>Pfizer: ELIQUIS product monograph 2018. <a target=xrefwindow id=d37824e3439 href="https://www.pfizer.ca/sites/g/files/g10050796/f/201903/ELIQUIS_PM_E_222811_12-Mar-2019_Marketed.pdf">Reference Source</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d37824e3449 class=n-a></a>Boehringer Ingelheim: PRADAXA product monograph 2019. <a target=xrefwindow id=d37824e3451 href="https://www.boehringer-ingelheim.ca/sites/ca/files/documents/pradaxapmen.pdf">Reference Source</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732926953"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d37824e3460 class=n-a></a>Steffel J, Verhamme P, Potpara TS, <i> et al.</i>: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Eur Heart J.</i> 2018; <b>39</b>(16): 1330–93. <a target=xrefwindow id=d37824e3471 href="http://www.ncbi.nlm.nih.gov/pubmed/29562325">PubMed Abstract </a> | <a target=xrefwindow id=d37824e3474 href="https://doi.org/10.1093/eurheartj/ehy136">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732926953">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jun 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-974.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-974.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Universit&eacute; de Paris, IRSL, Paris, France<br/> <sup>2</sup> Assistance Publique H&ocirc;pitaux de Paris, Saint-Louis Hospital, Internal Medicine, Autoimmune and Vascular Disease Unit, Paris, France<br/> <sup>3</sup> McGill University, Montral, QC, Canada<br/> <sup>4</sup> Sorbonne Universit&eacute;, INSERM UMRS_1166, Institute of Cardiometabolism And Nutrition, Paris, France<br/> <sup>5</sup> Assistance Publique H&ocirc;pitaux de Paris, Piti&eacute;-Salp&ecirc;tri&egrave;re Hospital, Department of Haematology, Paris, France<br/> <p> <div class=margin-bottom> Dominique Farge <br/> <span>Roles: </span> Investigation, Methodology, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Corinne Frere <br/> <span>Roles: </span> Investigation, Methodology, Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-974/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 27 Jun 2019, 8:974 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18673.1">https://doi.org/10.12688/f1000research.18673.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Farge D and Frere C. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20447 data-id=18673 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18673.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-974/v1/pdf?article_uuid=e876fd4b-5939-4a2a-8c26-b54904e4c43d" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18673.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Farge D and Frere C. Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):974 (<a href="https://doi.org/10.12688/f1000research.18673.1" target=_blank>https://doi.org/10.12688/f1000research.18673.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18673 id=mobile-track-article-signin-18673 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18673?target=/articles/8-974.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20447 /> <input name=articleId type=hidden value=18673 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Thein Hlaing Oo</strong>, Section of Thrombosis and Benign Hematology, The University of Texas M.D. Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Philippe Girard</strong>, Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jun 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-974.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-974.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53010-50501></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53011-50502></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-974/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>27 Jun 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Thein Hlaing Oo</strong>, Section of Thrombosis and Benign Hematology, The University of Texas M.D. Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Philippe Girard</strong>, Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-974.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-974/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the treatment and prevention...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-974/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-974/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-974/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Farge D and Frere C');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-974/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-974",
            templates : {
                twitter : "Recent advances in the treatment and prevention of venous thromboembolism.... Farge D and Frere C, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-974/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18673/20447")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20447");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "50500": 0,
                           "50501": 2,
                           "50502": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "fa58b15e-8721-41fa-a9ed-31501b491810";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-974.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-974.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-974.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-974.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-974.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>